source
- Novartis beats sales expectations as Q2 revenue rises to $14.4B, eyes upcoming study readoutsNovartis reported a modest rise in second‑quarter sales, lifting its share price after the company posted a 1% increase in net sales to $14.4 billion, surpassing analyst forecasts for a decline. A…
- Dyne Therapeutics receives early 2027 FDA decision date for Duchenne therapy, analysts anticipate smooth reviewDyne Therapeutics' investigational Duchenne muscular dystrophy therapy, zeleciment rostudirsen, has had its BLA accepted by the FDA with a target action date of Jan 21, 2027. Analysts at Oppenheim…